• Publications
  • Influence
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
TLDR
A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series
TLDR
This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases.
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
TLDR
It is shown that dying tumor cells release ATP, which then acts on P2X7 purinergic receptors from DCs and triggers the NOD-like receptor family, pyrin domain containing-3 protein (NLRP3)-dependent caspase-1 activation complex ('inflammasome'), allowing for the secretion of interleukin-1 β (IL-1β).
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues
TLDR
The authors' results confirmed previously reported data in the literature concerning isoforms expression in the most currently studied tissues and provided a great deal of new information, mainly about the expression of mRNA of little-known CYP isoforms.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
TLDR
The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer and outperformed the clinicopathological risk assessment in predicting all endpoints.
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
TLDR
It is shown that the release of the high mobility group box 1 protein by dying tumor cells is mandatory to license host dendritic cells (DCs) to process and present tumor antigens, and this knowledge may be clinically exploited to predict the immunogenicity and hence the efficacy of chemotherapeutic regimens.
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
TLDR
Results, obtained on the largest series analyzed thus far, show that TP53 mutations identified by gene sequencing have an independent prognostic value in breast cancer and could have potential uses in clinical practice.
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers
TLDR
This work provides further evidence for the involvement of miRNAs in sporadic breast cancer through down‐regulation of BRCA1 through binding to the same site in the 3′UTR of BrcA1 and down‐regulate its expression as demonstrated using reporter assays.
Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas.
TLDR
Although it failed to identify underexpression of specific target genes associated with DNMT increasing expression, the frequent overeexpression of DNMT3B in this breast tumor series points to DNMT 3B as a potential new therapeutic target in breast cancer.
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
TLDR
PIK3CA mutation is an emerging tumor marker which might become used in treatment-choosing process and should be now confirmed in larger series of patients included in randomized prospective ERBB2-positive breast cancer patients.
...
1
2
3
4
5
...